Compare Fortinet Inc (FTNT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs Incyte Corporation — how do they compare? Fortinet Inc trades at $162.56 (market cap $120.53B), while Incyte Corporation trades at $116.27 (market cap $22.99B). The key difference: Fortinet Inc is far larger — about 5.2× Incyte Corporation's market cap. Which is the better fit depends on your goals.
| FTNT | INCY | |
|---|---|---|
Market Cap | $120.53B | $22.99B |
Sector | Technology | Health |
52-Week High | $166.83 | $118.52 |
52-Week Low | $74.39 | $67.38 |
Enterprise Value | $117.73B | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $166.83, up 3.87% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $6.80B in 2025, with a net income margin of 27.49%, though valuation ratios like P/E of 63.76 and P/S of 17.5 appear elevated. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the company expanding its FortiEndpoint platform for AI security.
The outlook is positive due to robust earnings performance and sector tailwinds, but high valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $123.16 suggests caution relative to the current price, indicating potential overvaluation concerns amid growth optimism.
Incyte (INCY) trades at $114.88, up 0.57% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive Phase 1/2 data for VGA039 and European regulatory progress for Opzelura highlight pipeline momentum, while Q1 2026 EPS of $1.81 beat expectations by 35%.
The outlook remains positive with 52% analyst buy ratings and a consensus price target of $112.78, though risks include pipeline execution and competitive pressures. Revenue growth to $5.4B projected for 2026 supports valuation, but investors should monitor Q2 earnings due July 28, 2026 for confirmation of trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
